Eli Lilly's Mounjaro: A New Era in Cardiovascular Treatment Approved by FDA
Eli Lilly's Mounjaro gains FDA approval, signaling potential shifts in diabetes and cardiovascular care.
Moderna's Dual Catalysts: Bullish Sentiment Following Intismeran Success
Moderna's intismeran trial success and FDA approvals bolster bullish sentiment, signaling growth pot…
Eli Lilly's Mounjaro FDA Approval: A Game Changer for Investors
Eli Lilly's Mounjaro receives FDA approval for cardiovascular risk reduction, signaling potential gr…
Marvell Technology's Earnings Plunge: A Cautionary Tale for AI Investors
Marvell's stock dropped 8% post-earnings, highlighting the risks of high expectations in the tech se…
Canada's GDP Growth Signals Economic Resilience Amid Inflation Concerns
Canada's Q2 GDP growth of 3.3% showcases resilience but raises inflation worries as traders eye the …
Teva Pharmaceuticals Expands Neuroscience Portfolio with BXCL501 Acquisition Amid Growth Strategy
Teva Pharmaceuticals announces the proposed acquisition of BXCL501, enhancing its neuroscience pipel…
Revolution Medicines Achieves FDA Approval for RASONQUE: A Game Changer or Pricing Overhang?
Revolution Medicines' RASONQUE received FDA approval, but high pricing and muted stock response rais…
Zymeworks (ZYME) Stock Soars After FDA Approval: Is It a Buy?
Zymeworks' stock takes flight post-FDA approval, suggesting a promising future in cancer treatment. …
Merck (MRK) and Moderna (MRNA) Strike Gold in Melanoma Trial: What Investors Should Watch
Merck and Moderna's Phase 3 trial success could reshape cancer treatment and present new opportuniti…
Zymeworks' FDA Approval Sparks Analyst Optimism: What Investors Need to Know
Zymeworks' FDA approval for HER2+ cancer treatment has analysts bullish, raising the price target to…